Literature DB >> 16284466

Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.

Isaac M Malonza1, Florence Mirembe, Clemensia Nakabiito, Lawrence O Odusoga, Olubunmi A Osinupebi, Kamal Hazari, Shanta Chitlange, Mohamed M Ali, Marianne Callahan, Lut Van Damme.   

Abstract

BACKGROUND: An expanded Phase I trial was performed to assess the safety and acceptability of 6% cellulose sulfate gel (CS) in comparison with K-Y Jelly.
METHODS: Sexually abstinent (cohort I) and sexually active (cohort II) women in India, Nigeria and Uganda applied 3.5 ml of either 6% CS gel or K-Y Jelly for seven consecutive days. Safety was assessed by symptoms and signs (including colposcopy) of genital irritation, review of adverse events, and by changes in vaginal health as assessed by microscopy.
RESULTS: One hundred and eighty women (90 on CS and 90 on K-Y Jelly) were enrolled. Baseline characteristics of women in both gel groups were similar. In cohort I, six (14%) women on CS and 12 (27%) on K-Y Jelly reported genital symptoms, two (in K-Y Jelly group) of whom withdrew from the study. New colposcopy findings or findings showing deterioration were detected in four (9%) women on CS and nine (21%) women on K-Y Jelly in cohort I. Two women on CS and three on K-Y Jelly in cohort II reported genital symptoms. Five women (11%) in each gel group in cohort II had new colposcopy findings or findings showing deterioration. The differences between the gel groups were not statistically significant. The majority of women had no problem with their assigned product.
CONCLUSION: A vaginal application of 6% cellulose sulfate twice daily for seven consecutive days is as safe and well tolerated as a similar regimen of K-Y Jelly. Further development of 6% CS for prevention of HIV and pregnancy is recommended.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284466     DOI: 10.1097/01.aids.0000194797.59046.8f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  21 in total

Review 1.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

2.  Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception.

Authors:  Regine Sitruk-Ware; Vivian Brache; Robin Maguire; Horacio Croxatto; Narender Kumar; Sushma Kumar; Juan Carlos Montero; Ana Maria Salvatierra; David Phillips; Anibal Faundes
Journal:  Contraception       Date:  2007-04-18       Impact factor: 3.375

Review 3.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

Review 4.  Development of topical microbicides to prevent the sexual transmission of HIV.

Authors:  Robert W Buckheit; Karen M Watson; Kathleen M Morrow; Anthony S Ham
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

Review 5.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

Review 6.  Designing and developing suppository formulations for anti-HIV drug delivery.

Authors:  Anthony S Ham; Robert W Buckheit
Journal:  Ther Deliv       Date:  2017-08

7.  Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection.

Authors:  Anthony S Ham; Lisa Cencia Rohan; Ashlee Boczar; Lu Yang; Karen W Buckheit; Robert W Buckheit
Journal:  Pharm Res       Date:  2012-03-06       Impact factor: 4.200

Review 8.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

9.  A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Robert F Rando; Mohamed Labib; Fred C Krebs
Journal:  J Biomed Biotechnol       Date:  2010-05-31

10.  Enhancement of HIV infection by cellulose sulfate.

Authors:  Wang Tao; Chris Richards; Dean Hamer
Journal:  AIDS Res Hum Retroviruses       Date:  2008-07       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.